Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA Expands Approval Of Breast Cancer Drug Kisqali
FDA expands approval for drug to treat early-stage breast cancer
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. NBC News' Kathy Park speaks to a woman who took the drug while it was in clinical trials and is now cancer free.
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.
Breast cancer drug Kisqali gets FDA approval to prevent cancer recurrence
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce the chances of a patient's breast cancer coming back by 25%.
FDA expands approval of breast cancer drug Kisqali to earlier stage patients
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.
FDA Expands Use of Breast Cancer Drug Kisqali
Women with early-stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment, drug maker Novartis announced Tuesday.
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-posit
Anti-fibrotic drug shows promise in breast cancer
The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute to tumor cell growth, HER2. Despite this common trait, the development of HER2-negative cancers varies among patients,
FDA Approves Novartis' Kisqali as Adjuvant Treatment for Early-Stage HER2-Negative Breast Cancer
The drug is approved in combination with an aromatase inhibitor as adjuvant therapy for breast cancer patients at high risk of recurrence.
FDA expands approval of breast cancer drug Kisqali: What to know
The FDA expanded approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The decision will free up access to the medication for tens of thousands of people.
FDA expanded their approval on drug cancer drug
First News
Insight News
57m
Breast density and mammograms: New FDA rule will ensure all women have more information after cancer screenings
The Food and Drug Administration implemented a rule to go into effect on Sept. 10, 2024, requiring mammography facilities to notify women about their breast density. The goal is to ...
precisionmedicineonline
23h
Oncolytics Biotech Planning for Registration-Directed Pelareorep Trial in Advanced Breast Cancer
If it can secure the funds, Oncolytics will advance the agent into a pivotal study, based on positive data from the Phase I BRACELET-1 trial.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Kentucky judge fatally shot
$230 million crypto theft
Secret Service probing post
FCC chair denies Trump call
Boy kills bear, saves father
Families lose appeal
Cancels appearance w/ Duda
Ban called for in TX schools
Body found in SUV
To get a second moon
NYC subway joyride arrest
Man charged for threats
Disney to stop using Slack
Hold campaign event in MI
Recalling 449K+ vehicles
Collapse hazard recall
Stein's ballot bid rejected
MS sheriff's office probe
Vows to remain in race
PGA welcomes LIV players
Raises settlement offer
'Targeted strike' in Beirut
$3B for battery projects
FTC on privacy controls
Brazil threatens daily fines
To visit US next week
COVID, Wuhan market link
160M euros to Ukraine
Overdose deaths drop in US
Makes MLB history
Feedback